Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients S Mozzetti, C Ferlini, P Concolino, F Filippetti, G Raspaglio, S Prislei, ... Clinical Cancer Research 11 (1), 298-305, 2005 | 474 | 2005 |
Role of microRNAs in drug-resistant ovarian cancer cells A Sorrentino, CG Liu, A Addario, C Peschle, G Scambia, C Ferlini Gynecologic oncology 111 (3), 478-486, 2008 | 459 | 2008 |
Defining “mutation” and “polymorphism” in the era of personal genomics R Karki, D Pandya, RC Elston, C Ferlini BMC medical genomics 8, 1-7, 2015 | 354 | 2015 |
Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial M Hutchings, F Morschhauser, G Iacoboni, C Carlo-Stella, FC Offner, ... Journal of Clinical Oncology 39 (18), 1959, 2021 | 305 | 2021 |
Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients G Ferrandina, GF Zannoni, E Martinelli, A Paglia, V Gallotta, S Mozzetti, ... Clinical cancer research 12 (9), 2774-2779, 2006 | 302 | 2006 |
Inflammatory myofibroblastic tumor (inflammatory pseudotumor): DNA flow cytometric analysis of nine pediatric cases R Biselli, C Ferlini, A Fattorossi, R Boldrini, C Bosman Cancer: Interdisciplinary International Journal of the American Cancer …, 1996 | 210 | 1996 |
Synthesis of some pyrazole derivatives and preliminary investigation of their affinity binding to P-glycoprotein F Manna, F Chimenti, R Fioravanti, A Bolasco, D Secci, P Chimenti, ... Bioorganic & medicinal chemistry letters 15 (20), 4632-4635, 2005 | 205 | 2005 |
Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance C Ferlini, G Raspaglio, S Mozzetti, M Distefano, F Filippetti, E Martinelli, ... Molecular pharmacology 64 (1), 51-58, 2003 | 200 | 2003 |
Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines C Ferlini, G Scambia, M Marone, M Distefano, C Gaggini, G Ferrandina, ... British journal of cancer 79 (2), 257-263, 1999 | 194 | 1999 |
Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77 C Ferlini, L Cicchillitti, G Raspaglio, S Bartollino, S Cimitan, C Bertucci, ... Cancer research 69 (17), 6906-6914, 2009 | 182 | 2009 |
Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques C Ferlini, S Di Cesare, G Rainaldi, W Malorni, P Samoggia, R Biselli, ... Cytometry: The Journal of the International Society for Analytical Cytology …, 1996 | 155 | 1996 |
Hypoxia induces class III beta-tubulin gene expression by HIF-1α binding to its 3'flanking region G Raspaglio, F Filippetti, S Prislei, R Penci, I De Maria, L Cicchillitti, ... Gene 409 (1-2), 100-108, 2008 | 154 | 2008 |
In vitro evaluation of newly developed chalcone analogues in human cancer cells R De Vincenzo, C Ferlini, M Distefano, C Gaggini, A Riva, E Bombardelli, ... Cancer chemotherapy and pharmacology 46, 305-312, 2000 | 138 | 2000 |
The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance C Ferlini, G Raspaglio, S Mozzetti, L Cicchillitti, F Filippetti, D Gallo, ... Cancer research 65 (6), 2397-2405, 2005 | 134 | 2005 |
Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin S Giacomelli, D Gallo, P Apollonio, C Ferlini, M Distefano, P Morazzoni, ... Life sciences 70 (12), 1447-1459, 2002 | 126 | 2002 |
MiR-200c and HuR in ovarian cancer S Prislei, E Martinelli, M Mariani, G Raspaglio, S Sieber, G Ferrandina, ... BMC cancer 13, 1-14, 2013 | 125 | 2013 |
Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer D Gallo, S Giacomelli, C Ferlini, G Raspaglio, P Apollonio, S Prislei, ... European Journal of Cancer 39 (16), 2403-2410, 2003 | 124 | 2003 |
Myofibroblastic tumours: neoplasias with divergent behaviour. Ultrastructural and flow cytometric analysis R Biselli, R Boldrini, C Ferlini, C Boglino, A Inserra, C Bosman Pathology-Research and Practice 195 (9), 619-632, 1999 | 117 | 1999 |
Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma I De Stefano, G Raspaglio, GF Zannoni, D Travaglia, MG Prisco, M Mosca, ... Biochemical Pharmacology 78 (11), 1374-1381, 2009 | 112 | 2009 |
The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin T Servidei, C Ferlini, A Riccardi, D Meco, G Scambia, G Segni, C Manzotti, ... European Journal of Cancer 37 (7), 930-938, 2001 | 107 | 2001 |